Research programme: discovery therapeutics - OssianixAlternative Names: OSX500; OSX600; OSX700
Latest Information Update: 19 Jul 2016
At a glance
- Originator Ossianix
- Mechanism of Action G protein-coupled receptor antagonists; Ion channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 19 Jul 2016 Early research in Undefined indication in USA (unspecified route)